isatuximab
milatuzumab
melphalan flufenamide
belantamab mafodotin
atezolizumab
pacritinib
ozoralizumab
teclistamab
carfilzomib
inotuzumab
margetuximab
duligotuzumab
naxitamab
ruxolitinib
mapatumumab
oleclumab
panitumumab
cixutumumab
conatumumab
acrixolimab
ramucirumab
iratumumab
tigatuzumab
talacotuzumab
siltuximab
tenatumomab
vobarilizumab
robatumumab
teplizumab
Kahler's disease
dorlixizumab
pertuzumab
durvalumab
oportuzumab monatox
alacizumab
olendalizumab
lexatumumab
figitumumab
otilimab
volociximab
naptumomab estafenatox
pamrevlumab
-mab
tyrosine kinase inhibitor
monoantibody
drozitumab
deruxtecan
bimagrumab
evolocumab
matuzumab
caplacizumab
lintuzumab
nofetumomab
-toxa-
olutasidenib
brentuximab
amivantamab
immunotherapeutic
tabalumab
muromonab
onartuzumab
myelomatosis
citatuzumab bogatox
olaratumab
cergutuzumab
loncastuximab tesirine
ravulizumab
abagovomab
brolucizumab
afasevikumab
ivosidenib
gevokizumab
pidilizumab
tislelizumab
ocrelizumab
-les-
antinucleosome
lucatumumab
patritumab
myelomatous
antimonoclonal
bococizumab
avelumab
lorvotuzumab
amlitelimab
tisotumab
Alkeran
melphalan
agnogenic myeloid metaplasia
dostarlimab
obiltoxaximab
zanolimumab
spesolimab
antineoplastic antibiotic
immunomicroscopic
metelimumab
pritumumab
risankizumab
natalizumab
bezlotoxumab